国家集采胰岛素专项规则调整与中选结果变化的关联机制分析OA
Analysis of the association mechanisms between rule adjustment and change in selection outcomes of the national centralized drug procurement with volume-based purchasing program for insulin
目的 为国家组织药品集中带量采购胰岛素专项接续规则的完善提供参考.方法 基于公开政策资料、中选结果及访谈资料,采用政策文本分析、描述性统计分析、Wilcoxon符号秩检验和主题分析法,比较国家组织药品集中带量采购胰岛素专项首次采购与接续采购的规则及中选结果变化,分析规则调整与结果变化的关联机制.结果 与首次采购相比,接续采购延续了6个采购组和11个报价单元,最高有效申报价下调了40%,增设了竞价中选、复活中选和A类产品价格线.首次采购中选42个产品,接续采购中选49个,其中37个连续中选、5个退出、12个续约首中.同一采购组中,与首次采购相比,接续采购的价格极差显著降低(P=0.031),但两者均价比较的差异无统计学意义(P=0.063).国产企业更多进入A1分类,外资企业更多保留在B/C类.机制分析显示,价格线塑造了中选价格边界,分类和分量规则将企业报价与采购量预期相连接,可能改变企业报价激励,并与中选结果分布变化形成对应.结论 胰岛素专项接续采购通过价格线、产品分类和协议量分配等规则,形成价格边界、分量激励与供应约束相互衔接的机制,并与中选产品结构、价格分布及企业分类变化相对应,后续应强化合理价格区间、分量激励与供应履约的联动.
OBJECTIVE To provide evidence for further improving the rules governing the renewal round of national centralized drug procurement with volume-based purchasing(VBP)program for insulin.METHODS Based on publicly available policy documents,selection outcomes,and interview data,policy text analysis,descriptive statistical analysis,the Wilcoxon signed-rank test,and thematic analysis were used to compare the procurement rules and selection outcomes between the initial and renewal rounds of the national VBP programs for insulin,and to examine the mechanisms linking rule adjustments to changes in selection outcomes.RESULTS Compared with the initial round,the renewal round retained the six procurement groups and 11 bidding units,reduced the maximum valid bid price by 40%,and introduced competitive bidding selection,revival selection,and a price line for Category A products.A total of 42 products were selected in the initial round and 49 in the renewal round,including 37 that remained selected,5 that exited,and 12 that were newly selected in the renewal round.Within the same procurement groups,the price range decreased significantly in the renewal round compared with the initial round(P=0.031),whereas the difference in average price between the two was not statistically significant(P=0.063).Domestic manufacturers were more likely to enter the A1 category,whereas multinational manufacturers were more likely to remain in categories B/C.Mechanism analysis suggested that the price line shaped the boundary of selected prices,while the classification and volume-allocation rules linked manufacturers'bidding decisions to expected procurement volumes,potentially altering bidding incentives and corresponding to changes in the distribution of selection outcomes.CONCLUSIONS The renewal round of the insulin VBP program established an interrelated mechanism involving price boundaries,volume-based incentives,and supply constraints through the use of price lines,product classification,and contracted volume allocation.These rule adjustments corresponded to changes in the structure of selected products,price distributions,and manufacturer classifications.Future policy refinement should strengthen the coordination among reasonable price ranges,volume-based incentives,and supply performance.
王彪;汤庆伟;蒋欣;牛均予;贾韵;张天天
复旦大学公共卫生学院,上海 200032复旦大学公共卫生学院,上海 200032||上海市医药集中招标采购事务管理所,上海 200032复旦大学公共卫生学院,上海 200032复旦大学公共卫生学院,上海 200032复旦大学公共卫生学院,上海 200032复旦大学公共卫生学院,上海 200032
医药卫生
国家组织药品集中带量采购胰岛素接续采购中选结果规则调整关联机制
national centralized drug procurement with volume-based purchasinginsulinrenewal procurementselection outcomesrules adjustmentmechanisms
《中国药房》 2026 (19)
2491-2495,5
评论